First-in-class novel approach for targeting oncogenic proteins


At Nynex Therapeutics, we utilize a novel strategy to design first-in-class therapeutics to target previously difficult to inhibit oncogenic proteins. By designing inhibitors of deubiquitinating proteases (DUBs), we aim to create drugs that are able to specifically increase degradation of known cancer pro-survival proteins such as MCL-1 and ETS-1,  key anti-apoptotic and pro-proliferative proteins upregulated in many tumors.  If successful, this novel class of anticancer agents will one of the first therapeutics to target DUBs. 



Read more on the development of our novel therapeutics.

Learn More →


Get to know our drug development experts.

Learn More →